Clinical Imaging and Data Resources Core
临床影像和数据资源核心
基本信息
- 批准号:10573279
- 负责人:
- 金额:$ 28.84万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-15 至 2026-12-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAnimal ModelArchivesAwarenessBiological Specimen BanksBiomedical EngineeringBiometryBiostatistics CoreCancer CenterCancer Research ProjectCenters of Research ExcellenceCertificationClinicalClinical DataClinical ResearchCollaborationsCommunitiesComputer softwareCost effectiveness researchDataData AnalysesDatabasesDevelopmentEducational workshopEngineeringEnsureEvaluation IndexesExperimental DesignsFacultyGoalsHealth SciencesHistopathologyImageImaging technologyInfrastructureInstitutional Review BoardsJointsKnowledgeLeadershipLearningLinkMachine LearningMagnetic Resonance ImagingMedical ImagingMedical centerMetadataMethodologyMethodsModelingMonitorOklahomaPathologistPerformancePoliciesProspective StudiesProtocols documentationPublishingRegulationResearchResearch MethodologyResearch PersonnelResearch Project GrantsResearch SupportResourcesRetrospective StudiesSample SizeSamplingSampling StudiesSecureServicesSlideStainsStatistical Data InterpretationStudy modelsTestingThe Cancer Imaging ArchiveTrainingTranslational ResearchTreatment outcomeUnited States National Institutes of HealthUniversitiesValidationVertebratesWritingbiomedical imagingcancer diagnosiscentral databaseclinical biomarkersclinical imagingclinical translationcollegecommercializationcost effectivenessdata resourcedesigndigitalgraphical user interfacehuman subjecthuman subject protectionimaging biomarkerimaging studyinformatics infrastructuremachine learning methodmachine learning modelmemberoperationperformance testsprogramsquantitative imagingradiological imagingradiologistradiomicsshared databasestatisticssuccesstranslational cancer researchwelfare
项目摘要
ABSTRACT – Clinical Imaging and Data Resources Core
The overarching objective of this Clinical Imaging and Data Resources Core (CIDRC) is to provide research
project leaders (RPLs) of this COBRE with both regulatory and scientific support to facilitate their effort to conduct
medical imaging related translational cancer research projects. The CIDRC will serve as a crucial bridge between
the biomedical imaging research performed in the Gallogly College of Engineering on the University of Oklahoma
(OU) Norman campus and the clinical research community in the Stephenson Cancer Center (SCC) on the OU
Health Science Center (OUHSC) campus. Establishment of a robust, secure and durable mechanism and
platform for storing and sharing images, clinical samples, and associated data is critical to the development and
success of this proposed COBRE. The CIDRC will be organized to ensure the availability of scientifically valid
and well-characterized image data, and the compliance with all NIH regulatory requirements in conducting
human subject and animal model studies, as well as to encourage broad collaborative research efforts between
the biomedical imaging engineering and clinical research. The CIDRC will be established in the SCC of OUHSC
campus because OUHSC provides the broad clinical research service including the Institutional Review Board
(IRB) to examine and approve translational clinical research projects, the biostatistics Core, and services to
retrieve the archived medical images and the H&E stained histopathology slides, and other clinical data of cancer
diagnosis results and treatment outcome. This CIDRC will integrate and strengthen the existing clinical research
supporting resources located on the OUHSC campus to build a new and unique research resource platform to
train and support the RPLs and pilot awardees of this COBRE to conduct joint translational cancer research
projects on two OU campuses. The overall operation of the CIDRC will include to: (1) ensure that RPLs fully
understand all NIH policies and regulations for protection of human subjects and welfare of vertebrate animals,
(2) certify that study protocols for both retrospective and prospective studies are fully compliant with all NIH-
mandated regulatory requirements, (3) assist with the IRB protocol application writing and submission, (4)
provide biostatistics support to confirm that experiments are designed with appropriate sample sizes or statistical
power and the proper statistical data analysis methodologies are used to test and validate the underlying
hypothesis with high scientific rigor, and (5) establish a unique platform that can provide RPLs and other
researchers with the shared databases allowing access to the linked annotated medical images, biospecimens
and clinical data necessary to facilitate their proposed research projects. Thus, the CIDRC will build a critical
scientific and intellectual support infrastructure that aims to ensure the success of this COBRE as the RPLs
make progress in their research projects and transition to the independent researchers in conducting medical
imaging related translational cancer research with the high clinical impact and scientific rigor.
摘要 – 临床影像和数据资源核心
该临床影像和数据资源核心 (CIDRC) 的总体目标是提供研究
该 COBRE 的项目负责人 (RPL) 获得监管和科学支持,以促进他们开展工作
医学成像相关转化癌症研究项目。 CIDRC将成为双方之间的重要桥梁
俄克拉荷马大学加洛格利工程学院进行的生物医学成像研究
(OU) 诺曼校区和 OU 斯蒂芬森癌症中心 (SCC) 的临床研究社区
健康科学中心 (OUHSC) 校园。建立健全、安全、持久的机制
用于存储和共享图像、临床样本和相关数据的平台对于开发和共享至关重要
COBRE 提案的成功。 CIDRC 将组织确保提供科学有效的
和良好表征的图像数据,以及在进行时遵守所有 NIH 监管要求
人类受试者和动物模型研究,以及鼓励之间广泛的合作研究工作
生物医学成像工程和临床研究。 CIDRC将设在OUHSC的SCC
因为 OUHSC 提供广泛的临床研究服务,包括机构审查委员会
(IRB)审查和批准转化临床研究项目、生物统计学核心和服务
检索存档的医学图像和 H&E 染色的组织病理学幻灯片以及其他癌症临床数据
诊断结果和治疗结果。此次CIDRC将整合和加强现有的临床研究
支持位于 OUHSC 校园的资源,建立一个新的、独特的研究资源平台
培训和支持 RPL 和 COBRE 试点获奖者进行联合转化癌症研究
两个 OU 校区的项目。 CIDRC的总体运作将包括:(1)确保RPL充分
了解 NIH 关于保护人类受试者和脊椎动物福利的所有政策和法规,
(2) 证明回顾性和前瞻性研究的研究方案完全符合所有 NIH-
强制性监管要求,(3) 协助 IRB 协议申请的撰写和提交,(4)
提供生物统计学支持,以确认实验设计有适当的样本量或统计数据
使用力量和适当的统计数据分析方法来测试和验证底层
具有高度科学严谨性的假设,以及(5)建立一个独特的平台,可以提供 RPL 和其他
具有共享数据库的研究人员可以访问链接的带注释的医学图像、生物样本
以及促进他们提出的研究项目所需的临床数据。因此,CIDRC 将建立一个关键的
旨在确保 COBRE 作为 RPL 取得成功的科学和智力支持基础设施
研究项目取得进展,并过渡为独立研究人员进行医学研究
影像相关的转化癌症研究具有较高的临床影响力和科学严谨性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kathleen N. Moore其他文献
Extraperitoneal para-aortic lymph node evaluation for cervical cancer via pfannenstiel incision: technique and peri-operative outcomes.
通过 pfannenstiel 切口对宫颈癌进行腹膜外主动脉旁淋巴结评估:技术和围手术期结果。
- DOI:
10.1016/j.ygyno.2007.11.043 - 发表时间:
2008 - 期刊:
- 影响因子:4.7
- 作者:
Kathleen N. Moore;Michael A. Gold;D. Mcmeekin;J. Walker;T. Rutledge;Kristin K. Zorn - 通讯作者:
Kristin K. Zorn
Updates of the Precision Medicine Program in Gynecologic Oncology
- DOI:
10.1016/j.ygyno.2016.08.249 - 发表时间:
2016-10-01 - 期刊:
- 影响因子:
- 作者:
Erin E. Brown;Michelle R. Rowland;Kathleen N. Moore;Camille C. Gunderson - 通讯作者:
Camille C. Gunderson
Weekly Paclitaxel for Recurrent Ovarian Cancer: Does Weekly Administration at Primary Diagnosis Impact Efficacy and Toxicity at Recurrence?
- DOI:
10.1016/j.ygyno.2016.08.266 - 发表时间:
2016-10-01 - 期刊:
- 影响因子:
- 作者:
Camille C. Gunderson;Alexa Papaila;Kai Ding;Amelia M. Jernigan;Haider Mahdi;Sarah Bedell;David S. Miller;Bradley J. Monk;Kathleen N. Moore - 通讯作者:
Kathleen N. Moore
Incorporating immune checkpoint inhibitors in epithelial ovarian cancer
在上皮性卵巢癌中纳入免疫检查点抑制剂
- DOI:
10.1016/j.ygyno.2024.12.011 - 发表时间:
2025-02-01 - 期刊:
- 影响因子:4.100
- 作者:
Giorgio Bogani;Kathleen N. Moore;Isabelle Ray-Coquard;Domenica Lorusso;Ursula A. Matulonis;Jonathan A. Ledermann;Antonio González-Martín;Jean-Emmanuel Kurtz;Eric Pujade-Lauraine;Giovanni Scambia;Giuseppe Caruso;Francesco Raspagliesi;Nicoletta Colombo;Bradley J. Monk - 通讯作者:
Bradley J. Monk
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
叶酸受体α(FRα)靶向抗体-药物偶联物(ADC)mirvetuximab soravtansine 与贝伐珠单抗联合用于铂耐药卵巢癌患者的安全性和有效性
- DOI:
10.1016/j.ygyno.2023.01.020 - 发表时间:
2023-03-01 - 期刊:
- 影响因子:4.100
- 作者:
Lucy Gilbert;Ana Oaknin;Ursula A. Matulonis;Gina M. Mantia-Smaldone;Peter C. Lim;Cesar M. Castro;Diane Provencher;Sanaz Memarzadeh;Michael Method;Jiuzhou Wang;Kathleen N. Moore;David M. O'Malley - 通讯作者:
David M. O'Malley
Kathleen N. Moore的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kathleen N. Moore', 18)}}的其他基金
A Lead Academic Participating Site in Oklahoma for the Design and Conduct of NCTN Clinical Trials
俄克拉荷马州设计和进行 NCTN 临床试验的主要学术参与中心
- 批准号:
10360544 - 财政年份:2019
- 资助金额:
$ 28.84万 - 项目类别:
A Lead Academic Participating Site in Oklahoma for the Design and Conduct of NCTN Clinical Trials
俄克拉荷马州设计和进行 NCTN 临床试验的主要学术参与中心
- 批准号:
9889077 - 财政年份:2019
- 资助金额:
$ 28.84万 - 项目类别:
A Lead Academic Participating Site in Oklahoma for the Design and Conduct of NCTN Clinical Trials
俄克拉荷马州设计和进行 NCTN 临床试验的主要学术参与中心
- 批准号:
10582583 - 财政年份:2019
- 资助金额:
$ 28.84万 - 项目类别:
A Lead Academic Participating Site in Oklahoma for the Design and Conduct of NCTN Clinical Trials
俄克拉荷马州设计和进行 NCTN 临床试验的主要学术参与中心
- 批准号:
10158024 - 财政年份:2019
- 资助金额:
$ 28.84万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 28.84万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 28.84万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 28.84万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 28.84万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 28.84万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 28.84万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 28.84万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 28.84万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 28.84万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 28.84万 - 项目类别:
Grant-in-Aid for Early-Career Scientists














{{item.name}}会员




